These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 38542151)

  • 1. PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.
    Leiphrakpam PD; Are C
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non-coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles.
    Sanaei MJ; Baghery Saghchy Khorasani A; Pourbagheri-Sigaroodi A; Shahrokh S; Zali MR; Bashash D
    J Cell Physiol; 2022 Mar; 237(3):1720-1752. PubMed ID: 34897682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
    Barrett D; Brown VI; Grupp SA; Teachey DT
    Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway.
    Sun J; Zhao X; Jiang H; Yang T; Li D; Yang X; Jia A; Ma Y; Qian Z
    Tissue Cell; 2022 Aug; 77():101817. PubMed ID: 35679685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence.
    Narayanankutty A
    Curr Drug Targets; 2019; 20(12):1217-1226. PubMed ID: 31215384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-H4 facilitates proliferation and metastasis of colorectal carcinoma cell through PI3K/Akt/mTOR signaling pathway.
    Li C; Zhan Y; Ma X; Fang H; Gai X
    Clin Exp Med; 2020 Feb; 20(1):79-86. PubMed ID: 31664539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrroline-5-Carboxylate Reductase-2 Promotes Colorectal Cancer Progression via Activating PI3K/AKT/mTOR Pathway.
    Yin F; Huang X; Xuan Y
    Dis Markers; 2021; 2021():9950663. PubMed ID: 34512817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HOTAIR/miR-326/FUT6 axis facilitates colorectal cancer progression through regulating fucosylation of CD44 via PI3K/AKT/mTOR pathway.
    Pan S; Liu Y; Liu Q; Xiao Y; Liu B; Ren X; Qi X; Zhou H; Zeng C; Jia L
    Biochim Biophys Acta Mol Cell Res; 2019 May; 1866(5):750-760. PubMed ID: 30742932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.
    Yu L; Wei J; Liu P
    Semin Cancer Biol; 2022 Oct; 85():69-94. PubMed ID: 34175443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To Investigate the Occurrence and Development of Colorectal Cancer Based on the PI3K/AKT/mTOR Signaling Pathway.
    Zhong J; Ding S; Zhang X; Di W; Wang X; Zhang H; Chen Y; Zhang Y; Hu Y
    Front Biosci (Landmark Ed); 2023 Feb; 28(2):37. PubMed ID: 36866550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [LncRNA SNHG11 promotes malignant progression of colorectal cancer cells through the PI3K/Akt/mTOR signaling pathway].
    Tao SN; Liu XC; Wang YY; Yang H
    Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(10):758-765. PubMed ID: 38462356
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of Glut1 gene silencing on proliferation, differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-β/PI3K-AKT-mTOR signaling pathway.
    Wu XL; Wang LK; Yang DD; Qu M; Yang YJ; Guo F; Han L; Xue J
    J Cell Biochem; 2018 Feb; 119(2):2356-2367. PubMed ID: 28884839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
    Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
    Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways.
    Duan S; Huang W; Liu X; Liu X; Chen N; Xu Q; Hu Y; Song W; Zhou J
    J Exp Clin Cancer Res; 2018 Dec; 37(1):304. PubMed ID: 30518405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MUC3A promotes the progression of colorectal cancer through the PI3K/Akt/mTOR pathway.
    Su W; Feng B; Hu L; Guo X; Yu M
    BMC Cancer; 2022 Jun; 22(1):602. PubMed ID: 35655161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-talk between non-coding RNAs and PI3K/AKT/mTOR pathway in colorectal cancer.
    Moafian Z; Maghrouni A; Soltani A; Hashemy SI
    Mol Biol Rep; 2021 May; 48(5):4797-4811. PubMed ID: 34057685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent clinical advances in PI3K inhibitors on colorectal cancer.
    Zhu M; Jin Q; Xin Y
    Pharmazie; 2021 Dec; 76(12):568-573. PubMed ID: 34986950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor suppressive effect of scavenger receptor class A member 5 overexpression in colorectal cancer by regulating PI3K/AKT/mTOR pathway.
    Li Y; Peng F; Tan X; Wang J; Xu Y
    Genes Genomics; 2021 Oct; 43(10):1189-1198. PubMed ID: 34417976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma.
    Wu N; Du Z; Zhu Y; Song Y; Pang L; Chen Z
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818758772. PubMed ID: 29463194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.